VEGF-C–mediated lymphangiogenesis has also been shown to augment immunotherapy in a glioblastoma mouse model by increasing CD8+ T-cell priming in tumor-draining lymph nodes and promoting egress of tumor-specific CD8+ T cells to the primary tumor [99]. The gene discussed is CD8A; the disease is neoplasm.